Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies

Authors : Wei Xu, Garth Boehm, Qiang Zheng

Abstract

Governments that procure pharmaceutical products from an Essential Medicine List (EML) bear special responsibility for the quality of these products. In this article we examine the possibility of developing a pharmaceutical product quality risk assessment scheme for use by government procurement officials. We use the Chinese EML as a basis, and US recall data is examined as it is publically available.This is justified as the article is only concerned with inherent product quality risks. After establishing a link between Chinese essential medicines and those available in the US, we examine US recall data to separate product specific recalls. We conclude that, in addition to existing manufacturing based risks, there are two other product specific risks that stand out from all others, degradation and dissolution failure. Methodology for relative product risk for degradation is needed to be developed and further work is required to better understand dissolution failures which largely occur with modified-release solid oral products. We conclude that a product specific quality risk profile would be enhanced by including a risk assessment for degradation for all products, and in the case of solid oral products, dissolution.

Key Words

Chinese essential medicine; Product-specific quality risk; Chemical stability; Dissolution; Risk assessment; US recall data

Citation: Wei Xu, Garth Boehm, Qiang Zheng Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies doi:10.1016/j.apsb.2015.09.009

Received: 23 June 2015 Accepted: 17 September 2015 Available online: 17 December 2015

Copyright: © 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Acknowledgments

Sincere thanks to IMS Health for providing the pharmaceutical products volume data from 2009 to 2013 on the US market. We also thank the support of PKU-Hisun QbD Lab and PKU-Siyao Sterile GMP Lab.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024